“I just don’t think the evidence is there for these long lists,” said Dr. Molly Cooke, a professor of medicine at the University of California, San Francisco, who helped research a position paper on cannabis for the American College of Physicians. “It’s been so hard to study marijuana. Policy makers are responding to thin data.”
Even some advocates of medical marijuana acknowledge that the state laws legalizing it did not result from careful reviews of the medical literature.
“I wish it were that rational,” said Mitch Earleywine, chairman of the executive board of directors for Norml, a national marijuana advocacy group. Dr. Earleywine said state lawmakers more often ask themselves, “What disease does the person in a wheelchair in my office have?”
Read it all from the front page of today’s NY Times paper copy.
Also, make sure you did not miss this post earlier this week on the same topic featuring Nora Volkow of the National Institute on Drug Abuse.
Politicians' Prescriptions for Marijuana Defy Doctors and Data
“I just don’t think the evidence is there for these long lists,” said Dr. Molly Cooke, a professor of medicine at the University of California, San Francisco, who helped research a position paper on cannabis for the American College of Physicians. “It’s been so hard to study marijuana. Policy makers are responding to thin data.”
Even some advocates of medical marijuana acknowledge that the state laws legalizing it did not result from careful reviews of the medical literature.
“I wish it were that rational,” said Mitch Earleywine, chairman of the executive board of directors for Norml, a national marijuana advocacy group. Dr. Earleywine said state lawmakers more often ask themselves, “What disease does the person in a wheelchair in my office have?”
Read it all from the front page of today’s NY Times paper copy.
Also, make sure you did not miss this post earlier this week on the same topic featuring Nora Volkow of the National Institute on Drug Abuse.